Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma
Year: 2026
Type: article
Study design: Observational Study
Abstract: This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel). Participants completed health-related quality of life (HRQOL) and symptom surveys at enrollment/baseline (pre-lymphodepletion), infusion day(D)0, D7, D14, D21, D30, D60, and D90. Piecewise growth curve models assessed PRO trajectories pre-D7 and post-D7. Among 99 participants, ide-cel recipients (n = 49) were older than cilta-cel recipients (n = 50) (median 73 vs. 64 years, p < 0.001). Many PROs worsened pre-D7 and improved post-D7, including overall HRQOL, physical well-being, functional well-being, fatigue, physical function, and social function (p-values < 0.05). Several PROs were stable pre-D7 and improved post-D7, including anxiety, sleep disturbance, pain interference, and pain intensity (p-values < 0.05). There were differences between groups in the trajectories of social well-being pre-D7 (p = 0.01) and cognitive function post-D7 (p = 0.001). Patients with RRMM receiving standard of care CAR-T had similar PRO trajectories regardless of CAR-T type, with most PROs initially worsening or stable before significantly improving post-treatment. Future studies should investigate potential differences by treatment for social well-being and cognitive function as well as PRO trajectories beyond D90 post-treatment.
Source: Bone Marrow Transplantation
Authors: Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W7160824516